QCI Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

QCI Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-50	Closed	-$6K	–	637
2018 Q4	$6K	Buy	+50	New	+$7.42K	﹤0.01%	483
2015 Q2	–	Sell	-69	Closed	-$12K	–	519
2015 Q1	$12K	Hold	69	–	–	﹤0.01%	325
2014 Q4	$11K	Buy	+69	New	+$11.5K	﹤0.01%	354

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

QCI Asset Management's JAZZ Position: Q1 2019 in Review

QCI Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 50 shares — an estimated $6K sold.

QCI Asset Management first reported a position in JAZZ in Q4 2014 and held it in 3 quarters. The position peaked at $12K in Q1 2015. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

QCI Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
QCI Asset Management sold 50 Jazz Pharmaceuticals shares in Q1 2019, an estimated $6K.
QCI Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 3 quarters.
QCI Asset Management's Jazz Pharmaceuticals position peaked at $12K in Q1 2015.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on QCI Asset Management's 13F filing for Q1 2019, filed 15 May 2019.